NRG-GU011: A phase II double-blinded, placebo-controlled trial of prostate oligometastatic radiotherapy with or without androgen deprivation therapy in oligometastatic prostate cancer (NRG PROMETHEAN).
Publication
, Conference
Koontz, BF; Karrison, T; Pisansky, TM; Posadas, EM; Ballas, LK; Berlin, A; Hall, WA; Tran, PT; O'Daniel, JC; Hope, TA; Rodgers, JP; Feng, FY
Published in: JOURNAL OF CLINICAL ONCOLOGY
2023
Duke Scholars
Published In
JOURNAL OF CLINICAL ONCOLOGY
EISSN
1527-7755
ISSN
0732-183X
Publication Date
2023
Volume
41
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Koontz, B. F., Karrison, T., Pisansky, T. M., Posadas, E. M., Ballas, L. K., Berlin, A., … Feng, F. Y. (2023). NRG-GU011: A phase II double-blinded, placebo-controlled trial of prostate oligometastatic radiotherapy with or without androgen deprivation therapy in oligometastatic prostate cancer (NRG PROMETHEAN). In JOURNAL OF CLINICAL ONCOLOGY (Vol. 41).
Koontz, Bridget F., Theodore Karrison, Thomas Michael Pisansky, Edwin Melencio Posadas, Leslie K. Ballas, Alejandro Berlin, William A. Hall, et al. “NRG-GU011: A phase II double-blinded, placebo-controlled trial of prostate oligometastatic radiotherapy with or without androgen deprivation therapy in oligometastatic prostate cancer (NRG PROMETHEAN).” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 41, 2023.
Koontz BF, Karrison T, Pisansky TM, Posadas EM, Ballas LK, Berlin A, et al. NRG-GU011: A phase II double-blinded, placebo-controlled trial of prostate oligometastatic radiotherapy with or without androgen deprivation therapy in oligometastatic prostate cancer (NRG PROMETHEAN). In: JOURNAL OF CLINICAL ONCOLOGY. 2023.
Koontz, Bridget F., et al. “NRG-GU011: A phase II double-blinded, placebo-controlled trial of prostate oligometastatic radiotherapy with or without androgen deprivation therapy in oligometastatic prostate cancer (NRG PROMETHEAN).” JOURNAL OF CLINICAL ONCOLOGY, vol. 41, 2023.
Koontz BF, Karrison T, Pisansky TM, Posadas EM, Ballas LK, Berlin A, Hall WA, Tran PT, O’Daniel JC, Hope TA, Rodgers JP, Feng FY. NRG-GU011: A phase II double-blinded, placebo-controlled trial of prostate oligometastatic radiotherapy with or without androgen deprivation therapy in oligometastatic prostate cancer (NRG PROMETHEAN). JOURNAL OF CLINICAL ONCOLOGY. 2023.
Published In
JOURNAL OF CLINICAL ONCOLOGY
EISSN
1527-7755
ISSN
0732-183X
Publication Date
2023
Volume
41
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences